Treatment of bone marrow pathologies with polysufated polysaccharides
The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).
1. A method for the improving knee function in a human having bone marrow edema lesions as assessed by magnetic resonance imaging (MRI) and osteoarthritis 3-4 on the Kellgren-Lawrence scale in a knee, the method including determining that treatment of the knee with a corticosteroid has failed and administering intramuscularly an amount of pentosan polysulfate or an acceptable salt thereof, to the human in need of such treatment, in a manner so as to improve knee function by about 23% to about 89% as determined by Lysholm Knee Score.
2. The method according to claim 1 , wherein the pentosan polysulfate (PPS) is selected from the group consisting of: the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), the calcium salt of pentosan polysulfate (CaPPS), and the zinc salt of pentosan polysulfate (ZnPPS).
3. The method according to claim 2 , wherein the pentosan polysulfate (PPS) is sodium pentosan polysulfate (NaPPS).
4. The method according to claim 3 , wherein the treatment is by administering the sodium pentosan polysulfate or the acceptable salt thereof to the human in an effective amount of about 1 to 2 mg/kg of the human per dose or an effective amount of between about 25 mg and 300 mg as a fixed dose.
5. The method according to claim 3 , wherein the treatment is by administering the sodium pentosan polysulfate or the acceptable salt thereof to the human in an effective amount of about 2 mg/kg of the human per dose or an effective amount of about 150 mg as a fixed dose.
6. The method according to claim 3 , wherein administration is by dosing in a treatment regimen once daily, twice weekly or thrice weekly.
7. The method according to claim 6 , wherein administration is by dosing in a treatment regimen twice weekly.
8. The method according to claim 7 , wherein administration is by dosing in a treatment regimen twice weekly with a minimum of three days and a maximum of four days between dosages.
9. The method according to claim 8 , wherein administration is by dosing in a treatment regimen twice weekly for six weeks.
10. The method according to claim 9 , wherein the total dose of the sodium pentosan polysulfate or the acceptable salt thereof administered in the treatment regimen is about 200 to 4000 mg.
11. The method according to claim 1 , wherein pain associated with bone marrow oedema lesions in the mammal is reduced after treatment.
12. The method according to claim 1 , wherein the function of the knee is improved by about 23% to about 35%.
13. The method according to claim 1 , wherein the function of the knee is improved by about 23 to about 43%.
14. The method according to claim 1 , wherein the presence of bone marrow edema lesions is reduced as assessed by magnetic resonance imaging.
15. The method according to claim 1 , wherein the presence of bone marrow edema lesions is resolved as assessed by magnetic resonance imaging.
16. The method according to claim 1 , wherein the function of the knee is improved about 89%.